Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia

Abroad (travel likely)RecruitingPHASE2

Conditions

Immune Thrombocytopenia · Treatment

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
Contact: Study coordinator (Lei Zhang, MD) · zhanglei1@ihcams.ac.cn · +8602223909009
Contact: Study coordinator (Ting Sun, MD) · sunting@ihcams.ac.cn · +8602223909009

Study leads

Lei Zhang, MD
Principal Investigator
Institute of Hematology & Blood Diseases Hospital, China

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia · Treatment

Abroad (travel likely)RecruitingPHASE2

Tianjin, China

Anti-CD38 Antibody Treating Children With Primary Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia · Treatment

Abroad (travel likely)RecruitingPHASE2

Tianjin, China

Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia

Antiphospholipid Syndrome · Thrombocytopenia · Treatment

Abroad (travel likely)RecruitingPHASE2

Tianjin, China · Tianjin, China

A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune Thrombocytopenia

Immune Thrombocytopenia · Treatment

Abroad (travel likely)RecruitingPHASE2

Tianjin, China